Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Neutrophil/Lymphocyte Ratio ,Platelet/Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03630276
Recruitment Status : Unknown
Verified August 2018 by Shaza Mohamed Elreweny, Ain Shams University.
Recruitment status was:  Recruiting
First Posted : August 14, 2018
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
Shaza Mohamed Elreweny, Ain Shams University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia

Condition or disease Intervention/treatment Phase
Pre-Eclampsia Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 111 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Care Provider)
Primary Purpose: Diagnostic
Official Title: Evaluation of Neutrophil/Lymphocyte Ratio, Platelet /Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia
Actual Study Start Date : August 1, 2018
Actual Primary Completion Date : August 10, 2018
Estimated Study Completion Date : August 10, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Neutrophil/lymphocyte ratio Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Lab
Platelet/lymphocyte ratio Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Lab
CRP Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Lab


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. PREECLAMPSIA [ Time Frame: 6months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- PREECLAMPSIA from 25_45years

Exclusion Criteria:

  • chronic diseases Primary hypertension
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03630276


Locations
Layout table for location information
Egypt
Shaza Recruiting
Alexandria, Alex, Egypt, 12345
Contact: Shaza Mohamed Elreweny, Master    01090700297    Dr_shaza_elreweny@yahoo.com   
Sponsors and Collaborators
Ain Shams University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Shaza Mohamed Elreweny, Ain Shams University
ClinicalTrials.gov Identifier: NCT03630276    
Other Study ID Numbers: Shaza Elreweny
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Eclampsia
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications